Matinas BioPharma Holdings Inc (NYSE American:MTNB)

0.6821
Delayed Data
As of May 13
 +0.0115 / +1.71%
Today’s Change
0.49
Today|||52-Week Range
1.61
-32.47%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$148.8M

Company Description

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The firm's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers a broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Contact Information

Matinas BioPharma Holdings, Inc.
1545 Route 206 South
Bedminster New Jersey 07921-9999
P:(908) 484-8805
Investor Relations:

Employees

Shareholders

Other institutional6.56%
Mutual fund holders5.71%
Individual stakeholders11.19%

Top Executives

Jerome D. JabbourPresident, Chief Executive Officer & Director
Keith A. KucinskiChief Financial Officer
Raphael J. ManninoChief Scientific Officer & Senior Vice President
James J. FergusonChief Medical Officer
Hui LiuChief Technology Officer